Sam Cobb

Currus Biologics Wins FDA Clearance for CUR-001 Phase 1 Trial

America's medicines regulator has approved Currus Biologics to begin human trials of CUR-001, its solid-tumour CAR T-cell therapy combination, with dosing expected from early 2027.

Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours

Australian biotech Currus Biologics has won US regulator clearance to begin human testing of its lead cancer therapy, CUR-001; the company's backers include Brandon Capital, Main Sequence and Uniseed.

Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001

Australian biotech Currus Biologics has won US regulatory clearance to begin human testing of its lead cancer therapy, CUR-001, combining an antibody platform with CAR T cells for solid tumours.

Currus Biologics: a tale of perseverance, persistence and patience

Profile of a Peter Mac spinout advancing solid-tumour cell therapies; recounts its Series A backers, later investment, grant support, and chief executive Sam Cobb's earlier career building and listing AdAlta.

Our investment in Currus Biologics: Unlocking CAR-T for Solid Tumours

Main Sequence explains why it backed Currus Biologics, whose BEAT platform aims to make CAR-T cell therapies effective against solid tumours, starting with mesothelin-positive cancers, as the team prepares for a clinical trial.

Brandon Capital, Uniseed back cancer biotech start-up in $10m funding

Melbourne cancer immunotherapy startup Currus Biologics, spun out of Peter MacCallum, raised $10 million led by the Brandon Capital-managed Medical Research Commercialisation Fund with Uniseed, to advance its BEAT technology toward human trials.

Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·Startup Daily·SmartCompany·Startup Daily